Novel Procurement Deal To Rid England Of Hepatitis C
NHS England has struck a “first of its kind” agreement with Gilead, AbbVie and MSD to try to eliminate hepatitis C under which the companies will seek out patients who do not yet know they have the virus.
You may also be interested in...
Vertex has finally managed to reach an agreement to bring its cystic fibrosis drugs Orkambi and Symkevi to patients in England, which constitutes an important slice of what is the second biggest market for the drugs.
After years of stalemate, NHS England and Vertex have finally agreed a deal that will see cystic fibrosis patients access Orkambi and Symkevi as well as allow more patients to benefit from Kalydeco.
The “chronic disease paradigm” presents a real challenge for companies marketing advanced therapies.